Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
GSK just fired Moncef Slaoui from his post as Galvani Bioelectronics board chairman this week. The executive also served as the chief scientist for the U.S. government’s Operation Warp Speed, a coronavirus vaccine development group under Donald Trump’s administration.
CNBC reported that GlaxoSmithKline terminated Slaoui due to sexual harassment claims that were raised by a woman who was not named. His dismissal was announced by GSK on March 24.
The alleged offenses that led to Slaoui’s dismissal
Slaoui was a scientist and board chair at Galvani Bioelectronics, where GSK is a major shareholder. This is why it was GlaxoSmithKline that made the decision to get rid of him.
Moreover, it was revealed that in February, GSK received a letter that described Slaoui’s sexual harassment offenses and other misconducts committed toward the company’s employees. Based on the allegations, Dr. Slaoui’s inappropriate conduct happened several years ago when he was still working directly for GlaxoSmithKline.
After the concerns have been raised over the former board chairman’s behavior, GSK acted swiftly and axed the erring executive. His dismissal is effective immediately. At any rate, Slaoui lost his job 10 months after Trump appointed him to manage the country’s effort to develop COVID-19 vaccines.
“Dr. Slaoui's behaviors are wholly unacceptable,” GSK stated via a press release that was posted on March 24. “They represent an abuse of his leadership position, violate company policies, and are contrary to the strong values that define GSK's culture.”
It was added that everyone at GSK is expected to behave in accordance with the company’s values, especially its leaders. The firm then stressed that sexual harassment and other abuse of leadership are not tolerated and strictly prohibited.
About Moncef Slaoui
The fired Moncef Slaoui is 61 years old now and has been with GSK for 30 years. His wife, Kristen Slaoui, was a former GSK’s vice president and head of business development in the past.
When he was assigned as the chief advisor of Operation Warp Speed, he was a board member at Moderna pharmaceuticals. Due to criticisms for his connection to Moderna, while being an official at OWS, he resigned from the board of Moderna and sold his shares. However, Slaoui refused to give up his shares in GSK and said that those are his “retirement plan.”
